| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fiorenzo Mignini, Daniele Tomassoni, Enea Traini, Francesco Ament. Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen. Journal of neuroimmunology. vol 206. issue 1-2. 2009-04-02. PMID:19012970. |
based on the microanatomical localization of dopaminergic markers investigated, a role of dopamine in maturation and selection of lymphocytes and activation of immune responses is suggested. |
2009-04-02 |
2023-08-12 |
rat |
| Gwen Murphy, Amanda J Cross, Leah S Sansbury, Andrew Bergen, Adeyinka O Laiyemo, Paul S Albert, Zhuoqiao Wang, Binbing Yu, Teresa Lehman, Aravind Kalidindi, Rama Modali, Arthur Schatzkin, Elaine Lanz. Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial. International journal of cancer. vol 124. issue 9. 2009-04-02. PMID:19065655. |
dopamine and the dopaminergic reward pathway have been implicated in drug and alcohol addiction as well as obesity. |
2009-04-02 |
2023-08-12 |
Not clear |
| Jacobus P Petzer, Neal Castagnoli, Michael A Schwarzschild, Jiang-Fan Chen, Cornelis J Van der Schy. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 6. issue 1. 2009-04-02. PMID:19110205. |
because the therapeutic benefits of a(2a) antagonists are additive to that of dopamine replacement therapy, it may be possible to reduce the dose of the dopaminergic drugs and therefore the occurrence of side effects. |
2009-04-02 |
2023-08-12 |
Not clear |
| Fabrizio Stocch. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism & related disorders. vol 15 Suppl 1. 2009-03-31. PMID:19131046. |
there is now accumulating evidence that several factors - the progressive pathology of parkinson's disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors - are key contributors to the priming of the basal ganglia for induction of motor complications. |
2009-03-31 |
2023-08-12 |
Not clear |
| Alain Dagher, Trevor W Robbin. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron. vol 61. issue 4. 2009-03-30. PMID:19249271. |
these rare addictive syndromes, which appear to result from excessive dopaminergic medication use, illustrate the link between dopamine, personality, and addiction. |
2009-03-30 |
2023-08-12 |
Not clear |
| Haolan Ruan, Yi Yang, Xiaonan Zhu, Xuelan Wang, Ruzhu Che. Neuroprotective effects of (+/-)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice. Neuroscience letters. vol 450. issue 2. 2009-03-24. PMID:19070648. |
mptp caused the death of dopaminergic neurons in the substantia nigra and decreased the level of striatal dopamine. |
2009-03-24 |
2023-08-12 |
mouse |
| Haolan Ruan, Yi Yang, Xiaonan Zhu, Xuelan Wang, Ruzhu Che. Neuroprotective effects of (+/-)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice. Neuroscience letters. vol 450. issue 2. 2009-03-24. PMID:19070648. |
however, pretreatment with (+/-)-catechin was found to protect dopaminergic neurons in the substantia nigra against mptp toxicity, and restore the depletion of striatal dopamine in mice. |
2009-03-24 |
2023-08-12 |
mouse |
| Francisco J Diaz-Corrales, Masato Asanuma, Ikuko Miyazaki, Ko Miyoshi, Nobutaka Hattori, Norio Ogaw. Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotoxicity research. vol 14. issue 4. 2009-03-24. PMID:19073433. |
dopamine induces supernumerary centrosomes and subsequent cell death through cdk2 up-regulation in dopaminergic neuronal cells. |
2009-03-24 |
2023-08-12 |
Not clear |
| Francisco J Diaz-Corrales, Masato Asanuma, Ikuko Miyazaki, Ko Miyoshi, Nobutaka Hattori, Norio Ogaw. Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotoxicity research. vol 14. issue 4. 2009-03-24. PMID:19073433. |
the present study determined changes in cyclin e or cdk2 expression and in the centrosomal structure in dopaminergic neuronal cath.a cells exposed to 50, 100 and 150 micromolar dopamine (da) for 24 h. da induced significant increase in cdk2 protein and cyclin e protein, but not cyclin e mrna. |
2009-03-24 |
2023-08-12 |
Not clear |
| Michelle A Gauthier, Joseph K Eibl, James A G Crispo, Gregory M Ros. Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival. Neurotoxicity research. vol 14. issue 4. 2009-03-24. PMID:19073435. |
while zn(ii) is known to be toxic to some neuron subtypes, here we report a beneficial effect of zn(ii) on dopaminergic neurons and identify a mechanism through which metallothionein may scavenge toxic dopamine oxidation products. |
2009-03-24 |
2023-08-12 |
Not clear |
| Michelle A Gauthier, Joseph K Eibl, James A G Crispo, Gregory M Ros. Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival. Neurotoxicity research. vol 14. issue 4. 2009-03-24. PMID:19073435. |
these experiments suggest that zn(ii) enhances the survival of dopaminergic neurons, and we propose that as a mechanism, upregulated metallothioneins form covalent adducts with both dopamine and 6-hydroxydopamine, resulting in the observed neuroprotective effect of zn(ii) on these cells. |
2009-03-24 |
2023-08-12 |
Not clear |
| Rong Chen, Cheryse A Furman, Minjia Zhang, Myung N Kim, Robert W Gereau, Michael Leitges, Margaret E Gneg. Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. The Journal of pharmacology and experimental therapeutics. vol 328. issue 3. 2009-03-24. PMID:19098163. |
the dopamine transporter (dat) is a key mediator of dopaminergic neurotransmission and a major target for amphetamine. |
2009-03-24 |
2023-08-12 |
mouse |
| Béla Kiss, István Laszlovszky, Attila Horváth, Zsolt Némethy, Eva Schmidt, Gyula Bugovics, Károly Fazekas, István Gyertyán, Eva Agai-Csongor, György Domány, Zsolt Szombathely. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn-Schmiedeberg's archives of pharmacology. vol 378. issue 5. 2009-03-23. PMID:18551280. |
neurochemical comparison of rg-15 with antagonists having a different affinity and selectivity toward d3 and d2 receptors indicate that d3 receptors have little, if any, role in the control of presynaptic dopamine biosynthesis/release in dopaminergic terminal regions. |
2009-03-23 |
2023-08-12 |
mouse |
| Thomas Hillemacher, Helge Frieling, Thomas Hartl, Julia Wilhelm, Johannes Kornhuber, Stefan Bleic. Promoter specific methylation of the dopamine transporter gene is altered in alcohol dependence and associated with craving. Journal of psychiatric research. vol 43. issue 4. 2009-03-18. PMID:18504048. |
epigenetic regulation via promoter specific dna methylation of the dopamine transporter gene (dat) may influence altered dopaminergic neurotransmission in alcoholism. |
2009-03-18 |
2023-08-12 |
Not clear |
| Neil E Paterso. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. European journal of pharmacology. vol 603. issue 1-3. 2009-03-18. PMID:19101536. |
third, it is suggested that the unique mixed pharmacological profile of bupropion provides (1) attenuation of the multiple negative consequences of withdrawal via blockade of dopamine and noradrenaline reuptake; (2) replacement of the reward-facilitating and subjective effects of nicotine via blockade of dopaminergic reuptake; (3) attenuation of the rewarding effects of acute nicotine by nicotinic acetylcholine receptor blockade. |
2009-03-18 |
2023-08-12 |
Not clear |
| Agnès Nadjar, Charles R Gerfen, Erwan Bezar. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Progress in neurobiology. vol 87. issue 1. 2009-03-17. PMID:18938208. |
we propose, and hopefully will demonstrate, that priming does not exist per se but is the direct and intrinsic consequence of the loss of dopamine innervation of the striatum (and other target structures), meaning that the first injections of dopaminergic drugs only exacerbate those mechanisms (sensitization) but do not induce them. |
2009-03-17 |
2023-08-12 |
Not clear |
| Kenneth Blum, Amanda Lih Chuan Chen, Thomas J H Chen, Eric R Braverman, Jeffrey Reinking, Seth H Blum, Kimberly Cassel, Bernard W Downs, Roger L Waite, Lonna Williams, Thomas J Prihoda, Mallory M Kerner, Tomas Palomo, David E Comings, Howard Tung, Patrick Rhoades, Marlene Oscar-Berma. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theoretical biology & medical modelling. vol 5. 2009-03-16. PMID:19014506. |
thus, acute treatment should consist of preferential blocking of postsynaptic nucleus accumbens (nac) dopamine receptors (d1-d5), whereas long term activation of the mesolimbic dopaminergic system should involve activation and/or release of dopamine (da) at the nac site. |
2009-03-16 |
2023-08-12 |
Not clear |
| Asha Sahu, Kimberly R Tyeryar, Habiba O Vongtau, David R Sibley, Ashiwel S Undie. D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Molecular pharmacology. vol 75. issue 3. 2009-03-16. PMID:19047479. |
d5 dopamine receptors are required for dopaminergic activation of phospholipase c. dopamine activates phospholipase c in discrete regions of the mammalian brain, and this action is believed to be mediated through a d(1)-like receptor. |
2009-03-16 |
2023-08-12 |
mouse |
| Jonathan Brotchie, Cheryl Fitzer-Atta. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology. vol 72. issue 7 Suppl. 2009-03-12. PMID:19221312. |
many potential compensatory mechanisms have now been proposed; these are both dopaminergic, focused on enhancing effects or exposure to existing dopamine, and nondopaminergic, being focused on reducing activity of the indirect striatal output pathway. |
2009-03-12 |
2023-08-12 |
Not clear |
| I Omer Barlas, Mesut Cetin, M Emin Erdal, Umit B Semiz, Cengiz Basoglu, M Ertan Ay, Hasan Herken, Ozcan Uzu. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 150B. issue 1. 2009-03-10. PMID:18449897. |
it is hypothesized that molecular components of dopaminergic system, especially the dopamine d3 receptor gene (drd3), may play a crucial role in the pathophysiology of schizophrenia, because it is abundant in the limbic system of the brain and it binds antipsychotic drugs. |
2009-03-10 |
2023-08-12 |
Not clear |